Physician profile
Barry M Gaffney
NPI 1033102512
$11,439.78
in general payments reported to CMS, 2019-2025
26 companies · $1,992 in 2025
The $1,992 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,394 · 2020: $196 · 2021: $947 · 2022: $1,271 · 2023: $2,843 · 2024: $1,798 · 2025: $1,992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,133 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,132.72 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,804.39 | 2019-2025 | Dailies Total1, Total30, Dailies Total1 Multifocal |
| Johnson & Johnson Vision Care, INC. | $2,369.64 | 2022-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $1,774.72 | 2022-2025 | Infuse, Xiidra, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,448.40 | 2019-2021 | |
| Sight Sciences, INC. | $577.50 | 2019-2025 | Tearcare System |
| Coopervision INC. | $496.55 | 2019-2025 | Myday Contact Lens, Biofinity Contact Lens |
| Amgen INC. | $271.55 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $203.12 | 2020-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $178.44 | 2021 | |
| Shire North American Group INC | $173.96 | 2019 | |
| Oyster Point Pharma, INC. | $171.89 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Abb Con-Cise Optical Group LLC | $170.03 | 2019-2023 | Spectacle Lenses, Contact Lens |
| Dompe US, INC. | $129.36 | 2021-2025 | Oxervate |
| Abbvie INC. | $124.98 | 2025 | |
| Horizon Therapeutics Plc | $121.12 | 2023 | Tepezza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $77.68 | 2019 | |
| Tearlab Corp | $76.19 | 2021 | |
| Optovue, INC. | $59.52 | 2019 | |
| Genzyme Corporation | $50.00 | 2024 | |
| Thea Pharma INC. | $45.52 | 2022 | |
| Astellas Pharma US INC | $23.76 | 2024 | Izervay |
| Tarsus Pharmaceuticals, INC. | $23.54 | 2024 | Xdemvy |
| Optos, INC. | $21.29 | 2020 | |
| Allergan, INC. | $17.77 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.62 | 2019 | |
| Alcon Research LLC | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Gaffney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.